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ABSTRACT

Recently, we have shown that neuropeptide Y (NPY) is produced and
upregulated in visceral adipose tissue of an early-life programmed rat model of
central obesity. Moreover, we have demonstrated that NPY contributes to the
pathogenesis of obesity. However, the role of NPY in regulating adipocyte
metabolism is poorly understood. The present study examined the effects of NPY
on adipocyte metabolism using 3T3-L1 adipocytes. We found that NPY
potentiated

isoproterenol

(P-adrenergic agonist) stimulated lipolysis. This

potentiation occurred upstream of adenylyl cyclase, since NPY did not enhance
forskolin

(direct activator of adenylyl cyclase) stimulated

lipolysis. The

potentiation was mediated by increased phosphorylation of hormone sensitive
lipase. In contrast, NPY did not alter the expression of several key lipolytic and
lipogenic enzymes/proteins or glucose uptake. Our results revealed a novel cross
talk between the NPY and 3-adrenergic signaling pathways in regulating lipolysis
and added a new dimension to the role NPY plays in regulating energy balance.

Keywords: neuropeptide y, adipocyte, lipolysis, lipogenesis, glucose uptake,
potentiation, beta adrenergic receptor signalling, 3T3-L1, hormone sensitive
lipase, isoproterenol
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Chapter 1
Introduction
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1.1 Obesity Epidemic
Obesity is broadly defined as increased body weight caused by an excess
accumulation of adipose tissue [Dixon, 2010]. Clinically, an individual with a body
mass index of greater than 30 is considered obese. In recent years, the
incidence and prevalence of obesity has increased at an alarming rate to
epidemic levels in both developed and developing countries [James, 2008].
According to the 2004 Canadian Community Health Survey: Nutrition, 1 in 4
Canadians is obese and 59% of adult Canadians are overweight [CIHI, 2004],
Moreover, obesity rates are also rising among children [De Onis et al., 2010].
Obesity is a serious medical issue because it impairs quality of life and
increases the risk for cardiovascular disease, metabolic syndrome, cancer and a
host of other chronic illnesses [Dixon, 2010]. There are different types of obesity
that have been defined based on the topography of fat deposition and studies
have shown that visceral or central obesity represents the greatest risk factor for
the subsequent development of disease [Montague and O'Rahilly, 2000].
Currently, there is a lack of effective therapeutic interventions and thus, the
primary focus is on prevention [Lang and Froelicher, 2006]. Altogether, there is a
pressing need for more effective preventative and treatment options. However, a
better understanding of the processes that underlie the development and
maintenance of obesity are first required.
1.1.1 Etiology of Obesity
Obesity can result from an increase in cell size (hypertrophy), cell number
(hyperplasia) or both [Jo et al., 2009]. Fundamentally, obesity is the result of a

chronic imbalance between energy storage and energy expenditure. However, it
is a complex and multi-factorial disease because the interaction between genetic
and environmental factors in numerous systems impacts energy balance
[Hofbauer, 2002]. It is estimated that approximately 50% of the variation in body
fat can be accounted for by genetic factors [Campfield and Smith, 1999] and a
number of genes have been identified that are associated with the development
of obesity including the genes that code for leptin and the fat mass and obesityassociated protein [Walley et al., 2009]. However, it is environmental and lifestyle
factors that are responsible for the rapid increase in obesity worldwide [James,
2008].

1.2 Fetal Origins of Adult Disease
In recent years, one environmental influence that has gained increased
interest is the in utero environment [Morley, 2006]. A number of studies have
found a strong statistical association between poor fetal growth and the
subsequent development of hypertension, insulin resistance, coronary heart
disease and metabolic syndrome [Morley, 2006]. These observations were
initially made by Barker and colleagues [Barker et al., 1993] . Since then, these
finding has been replicated in a number of populations [Byrne and Phillips, 2000].
These studies have lead to the development of the fetal origins of adult disease
hypothesis which postulates that a sub-optimal in utero environment leads to the
programming of fetal tissues [Ozanne, 2001], This programming leads to
permanent alterations in metabolism and predisposes the individual to

developing

disease

later

in life.

Currently,

the

molecular mechanisms

underpinning this programming are an area of intensive investigation.
A number of animal models have been developed to investigate the fetal
origins of adult disease [Bertram and Hanson, 2001]. In these models, the effects
of a variety of insults are explored including maternal malnutrition, maternal
diabetes, hypoxia, maternal anaemia and overexposure to glucocorticoids. The
maternal protein restriction (MPR) rat model is one of the most widely utilized
models [Ozanne, 2001]. In this model, pregnant rat dams are fed an isocaloric
low-protein diet consisting of 8% protein rather than the 20% protein found in the
control diet [Holemans et al., 2003]. Dams are fed this diet throughout pregnancy
and lactation and the resultant offspring are growth restricted. These MPR
offspring go on to develop visceral obesity, hypertension, insulin resistance and
metabolic syndrome. Overall, animal models provide strong experimental
evidence supporting the epidemiological studies done in humans and will be
valuable in uncovering the mechanisms linking insults to fetal development and
adult disease [Bertram and Hanson, 2001].

1.2.1 Fetal Programming of Adipose Tissue
To date, a number of tissues have been shown to be structurally and
functionally affected by in utero programming in humans and animal models
[Byrne and Phillips, 2000; Bertram and Hanson, 2001]. These include alterations
in the cardiovascular system, pancreas, muscle and liver. Given that MPR
offspring develop visceral adiposity, our lab sought to investigate the underlying

molecular mechanisms [Guan et al., 2005], To examine if adipose tissue plays a
role in the fetal programming of obesity, our lab isolated visceral adipose tissue
(VAT) from control and male MPR offspring and performed a microarray analysis.
Analysis of the data revealed a distinct pattern of gene expression in the adipose
tissue of MPR offspring [Guan et al., 2005]. The pattern of gene expression
supported an increase in preadipocyte proliferation, adipocyte differentiation and
lipogenesis. Furthermore, there was an upregulation in pro-angiogenic factors
and angiogenesis is a prerequisite to adipose tissue expansion [Voros et al.,
2005]. Taken together, the profile of gene expression supports an increase in
adipogenesis and angiogenesis which explains the visceral adiposity of MPR
offspring [Guan et al., 2005],
Further evidence that maternal protein restriction results in programming
of adipose tissue comes from preadipocytes isolated from VAT of male MPR
offspring [Zhang et al., 2007], Our lab found that preadipocytes from MPR
offspring displayed a two fold increase in the rate of proliferation. This increase
seemed to be due to an inherent aberration because the increased proliferation
persisted even in subculture. These findings along with our microarray data
demonstrate that adipose tissue metabolism and development are permanently
altered by maternal protein restriction [Guan et al., 2005; Zhang et al., 2007].
Therefore, programming of adipose tissue represents an important link between
growth restriction and the development of obesity.

6

1.2.1.1 Candidate Gene Approach
To expand upon our findings, we took advantage of our previously
published microarray data and used a candidate gene approach to select targets
for further investigation. In our MPR rat model, male rats develop visceral obesity
that is characterized by hyperplasia but not hypertrophy [Guan et al., 2005].
Accordingly, candidate genes were selected based on the criteria that they 1) are
known to stimulate cell proliferation of nonadipose cells and 2) their expression is
upregulated in VAT from our animal model. A candidate gene that was identified
was neuropeptide Y (NPY) which stimulates proliferation in different cell types
[Hansel et al., 2001; Pons et al., 2003] and is upregulated by 6-fold in our early
life rat model of visceral obesity [Guan et al., 2005].

1.3 Neuropeptide Y
NPY was first isolated from porcine brain [Tatemoto et al., 1982] and
belongs to a family of structurally related peptides, which includes peptide YY
and pancreatic polypeptide [Silva et al., 2002]. The common structural feature of
these peptides is a tertiary three-dimensional pancreatic polypeptide fold. NPY is
synthesized as a prepropeptide that undergoes posttranslational processing
which results in the active 36 amino acid peptide. Functions of NPY are mediated
by five distinct receptor subtypes (known as Yi, Y2, Y4, Y5, and Y6), which all
belong to the G protein-coupled receptor superfamily [Yulyaningsih et al., 2011].
The NPY receptors are coupled to pertussis toxin sensitive G¡ or Go
heterotrimeric G-proteins. When activated, they induce a decrease in the

7

intracellular concentration of cAMP and/or an increase in intracellular calcium
concentration depending on the cell type. There are a number of specific
pharmacological agonists and antagonists that have been developed that have
high affinities for the various receptor subtypes [Kamiji and Inui, 2007],
Additionally, mice in which NPY and specific NPY receptors are knocked out
have been generated [Thorsell and Heilig, 2002]. NPY and receptor knockouts
are grossly normal which suggests a redundancy of the system or the presence
of compensatory mechanisms. However, the combination of knockout models
and specific pharmacological tools has been valuable to study NPY’s numerous
physiological

functions

and

elucidate

the

receptor

subtypes

involved

[Yulyaningsih et al., 2011],

1.3.1 Central Effects of NPY
NPY is one of the most abundant neuropeptides in the brain and the
highest levels are found in the hypothalamus, particularly in the arcuate nucleus
(ARC) and paraventricular nucleus (PVN) [Higuchi et al., 1988], It is also highly
expressed in the cerebral cortex and moderate levels are found in the amygdala,
hippocampus and basal ganglia [Thorsell and Heilig, 2002]. Corresponding to its
widespread distribution, NPY has been implicated in regulating a number of
physiological functions in the central nervous system

[Silva et al., 2002;

Pedrazzini et al., 2003], Studies have found that NPY decreases anxiety in a
number of animal models, reduces seizure activity, inhibits alcohol consumption
and plays a role in memory retention.

One of the most well studied roles for NPY is in the central regulation of
appetite [Kalra and Kalra, 2003]. NPY is the most potent appetite stimulating
hormone in the brain and the drive to feed is mediated by the ARC and PVN.
NPY expression in the PVN and ARC is increased during fasting and decreases
after feeding [Kalra et al., 1991], Intracerebroventricular (ICV) administration of
NPY to mice and rats produces hyperphagia [Raposinho et al., 2001], When
administration is maintained, animals become obese and develop metabolic
syndrome. Furthermore, hypothalamic NPY expression is increased in fatty
Zucker rats and in the leptin-deficient ob/ob mouse model of obesity [Silva et al.,
2002], Knockout of NPY in ob/ob mice was found to attenuate the obese
phenotype indicating that leptin’s physiological action is facilitated in part by
suppression of NPY expression [Erickson et al., 1996], In addition to its direct
orexigenic effects, NPY infused centrally was found to decrease the expression
of anorexigenic signals that produce satiety [Raposinho et al., 2001]. Overall,
hypothalamic NPY plays a critical role in the encoding of appetite and increased
expression leads to the development of obesity and metabolic syndrome.

1.3.2 NPY and Adipose Tissue
1.3.2.1 Production of NPY by Adipose Tissue
Classically, NPY was thought to contribute to the pathogenesis of obesity
mainly through its potent stimulation of appetite in the hypothalamus. Recently,
this dogma has been challenged by the identification of adipose tissue as a novel

peripheral site of NPY biosynthesis by us [Yang et al., 2008] and others [Kos et
al., 2007; Kuo et al., 2007]. In addition to being upregulated in VAT of our earlylife model of visceral obesity, our lab found that NPY expression was upregulated
in VAT of obese Zucker rats [Yang et al., 2008]. Furthermore, Kuo and
colleagues reported a similar upregulation of NPY expression in adipose tissue of
a diet and cold stress induced mouse model of obesity [Kuo et al., 2007],
Collectively, the upregulation of NPY expression in adipose tissue of several
distinct rodent models of obesity underscores an important peripheral role for
NPY in the pathogenesis of obesity.

1.3.2.2 NPY and Adipose Tissue Expansion
In support of a peripheral role for NPY in the development of obesity, an
NPY implant in adipose tissue was found to increase both its weight and volume
[Kuo et al., 2007]. In the same study, Kuo et al. found that NPY stimulated
angiogenesis in adipose tissue and the formation of new blood vessels is a
requirement for adipose tissue expansion. Furthermore, our lab found that NPY
strongly stimulated 3T3-L1 preadipocyte proliferation through the Yi receptor and
subsequent activation of the extracellular related kinase 1/2 pathway [Yang et al.,
2008], Since mature adipocytes do not multiply, the proliferation of adipocyte
precursor cells is another critical pre-requisite to adipose tissue expansion [Otto
and Lane, 2005]. Finally, several studies using isolated adipocytes from mice, rat,
dog and humans have shown that NPY inhibits lipolysis [Valet et al., 1990;
Castan et al., 1994; Serradeil-Le Gal et al., 2000], However, the mechanisms of

action require further investigation and these systems commonly suffer from the
drawback of effects due to cell breakage [Large et al., 2004], Overall, the effects
of NPY in adipose tissue and its roles in regulating adipocyte metabolism are still
poorly understood and need to be explored.

1.4 Metabolic Functions of Adipocytes
1.4.1 3T3-L1 Cell Line
A number of immortalized cell lines have been used to study adipocyte
differentiation and physiology [Grégoire et al., 1998]. 3T3-L1 cells are mouse
embryonic fibroblasts that were clonally isolated from 3T3 cells derived from
disaggregated embryos [Green and Kehinde, 1974], These preadipocytes are
committed to the adipocyte lineage and when stimulated appropriately undergo
terminal differentiation into mature adipocytes. 3T3-L1 adipocytes have the
biochemical and morphological properties of adipocytes [MacDougald and Lane,
1995]. They have been found to faithfully recapitulate the properties of
adipocytes isolated from adipose tissue and are a well established in vitro model
system to study adipocyte physiology and metabolism.
1.4.2 Lipolysis
Adipose tissue is the largest store of reserve energy in the body [Zechner
et al., 2009], During times of energy deficit, energy stored in adipocytes primarily
in the form of triglycerides can be mobilized to meet energy requirements.
Lipolysis is the process of energy mobilization and involves the hydrolysis of
triglycerides releasing glycerol and free fatty acids for utilization by other tissues.

Adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and
monoglyeride lipase (MGL) are responsible for the three hydrolytic reactions in
the lipolysis reaction [Duncan et al., 2007], In addition, a number of other proteins
such as perilipin and adipocyte lipid binding protein are required in facilitating
lipolysis.

1.4.2.1 Components of the Lipolytic Pathway
1.4.2.1.1 Adipose Triglyceride Lipase
ATGL is a recently discovered triglyceride hydrolase that is associated
with lipid droplets [Zimmermann et al., 2004], ATGL plays a crucial role in the
lipolytic pathway since ATGL deficient mice become obese and have a 75%
reduction in fat cell lipolysis [Haemmerle et al., 2006], It has high substrate
specificity for triacylglycerol and is responsible for catalyzing the first hydrolysis
reaction producing diacylglycerol and a free fatty acid. To perform its lipolytic
function, ATGL requires a co-activator known as a/p hydrolase domaincontaining protein 5 (ABHD5), also known as comparative gene identification-58
(CGI-58) [Zechner et al., 2009]. The presence of ABHD5 increased mouse ATGL
activity by approximately 20 fold and increased activation of human ATGL by 5
fold. When ABHD5 expression is silenced in human fat cells, the lipolytic action
of ATGL is abolished. Moreover, it has been shown that ATGL activity is
associated with its expression and overexpression of ATGL in a mouse fat cell
line increased lipolysis while its knockdown decreased lipolysis [Lafontan and
Langin, 2009], Importantly, ATGL expression has been shown to be affected by

several hormones including insulin and tumor necrosis factor-alpha [Kralisch et
al., 2005]. However, given its recent discovery, there is still much work to be
done on investigating the regulation of ATGL activity.

1.4.2.1.2 Hormone Sensitive Lipase
HSL is expressed in a number of tissues including muscle, pancreatic (3cells, macrophages and white adipose tissue [Lafontan and Langin, 2009]. In
adipose tissue, it plays a crucial role in lipid metabolism and is an important
regulatory step in the lipolytic pathway [Holm et al., 2000b]. HSL possesses
broad substrate specificity and is able to hydrolyze triacylglycerol, diacylglycérol,
monoacylglycerol, steroid fatty acid esters and retinyl esters. In terms of
triglyceride lipolysis, it has a much higher hydrolase activity against diacylglycérol
compared to triacylglycerol [Schweiger et al., 2006]. The structure of HSL is
composed of at least two domains [Holm et al., 2000b]. The N-terminal domain
has been proposed to play a role in binding to lipid droplets and interaction with
other protein partners. The C-terminal catalytic domain contains the catalytic site
and also includes a regulatory module that has four phosphorylation sites.

1.4.2.1.2.1 Regulation of HSL Activity
HSL contains a regulatory module that has a number of serine residues
that can be phosphorylated by different kinases [Lafontan and Langin, 2009].
Ser-563, Ser-659, and Ser-660 are targets of protein kinase A (PKA) and
phosphorylation of these residues leads to an increase in HSL activity. In

contrast, Ser-565 is phosphorylated by AMP-activated protein kinase which
sterically inhibits phosphorylation of Ser-563 and therefore decreases HSL
activity [Carmen and Victor, 2006]. To date, two phosphatases (PP) PP2A and
PP1 are believed to play a role in the dephosphorylation of HSL [Lafontan and
Langin, 2009]. Altogether, HSL enzyme activity can be controlled through its
phosphorylation status.
In addition to phosphorylation, HSL function is also regulated by its cellular
localization [Wang et al., 2009].Under basal conditions, HSL is primarily localized
to the cytosol of adipocytes. However, upon beta-adrenergic stimulation and HSL
phosphorylation, HSL translocates to the surface of lipid droplets. HSL
subsequently binds to proteins at the surface of the lipid droplet which further
activates HSL and facilitates its access to the lipids contained within the droplet.
This translocation process is critical to the lipolytic function of HSL but is still
poorly understood.

1.4.2.1.3 Monoglyceride Lipase
Monoglyceride lipase (MGL) is responsible for catalyzing the final
hydrolysis reaction in the lipolytic process [Duncan et al., 2007], It has high
substrate specificity and only has catalytic activity against monoacylglycerols.
The catalytic site of MGL including the catalytic triad has been identified and
mutation of Ser122, Asp239 or His269 abolishes lipase activity. However, MGL is
expressed at high levels in adipocytes and is thought to not be rate limiting
because of its abundance.
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1.4.2.1.4 Perilipin
Perilipin is a protein that is abundantly expressed in adipocytes and coats
the surface of lipid droplets [Martinez-Botas et al., 2000]. Perilipin has been
found to be a critical regulator of lipolysis [Tansey et al., 2004], Under basal
conditions, perilipin restricts access of lipases to the triglycerides contained within
the droplet. In addition, perilipin is bound to ABHD5 which sequesters it and
keeps it from activating ATGL. Upon stimulation, perilipin is phosphorylated at
multiple sites by PKA. Once perilipin is phosphorylated, the lipid droplet
undergoes a structural remodelling and the central lipid droplet becomes
fragmented into smaller micro droplets allowing for greater access of the lipases
to their substrates [Brasaemle, 2007]. In addition, upon perilipin phosphorylation,
ABHD5 is released and activates ATGL activity. Finally, perilipin facilitates the
interaction between lipases and the lipid droplet by acting as a docking site
[Tansey et al., 2004]. The study found that HSL translocation did not occur when
PKA phosphorylation sites of perilipin were mutated. Thus, under basal
conditions perilipin acts to inhibit lipolysis but under stimulated conditions,
perilipin is critical for mediating lipolysis and is required to achieve maximal
lipolytic rates.

1.4.2.2 Beta-adrenergic Stimulated Lipolysis
In terms of regulation, there are a number of hormones and signalling
molecules that form a complex network and allows for the precise control of the
lipolytic rate [Lafontan and Langin, 2009]. Catecholamines are the most

important lipolytic stimulus in vivo and stimulate lipolysis through beta-adrenergic
receptors [Coleman and Mashek, 2011]. Murine adipose tissue expresses (31, 32
and 33 adrenergic receptors while human adipose tissue only possesses 31 and
32 receptors [Langin, 2006]. 3-adrenergic receptors in adipose tissue are
coupled to the Gs heterotrimeric G-protein. Figure 1.1 illustrates the stepwise
hydrolysis of triglyceride and the signalling events that follow 3-adrenergic
receptor activation.
White adipose tissue is innervated by the sympathetic nervous system and
the primary postganglionic neurotransmitter is norepinephrine [Bartness and
Bamshad, 1998]. In isolated fat pads from rats, stimulation of these nerves
promotes lipid mobilization, and denervation of fat pads has been found to
decrease lipolysis. Besides sympathetic stimulation, adipose tissue is highly
vascularized

[Lijnen,

2008].

During

fasting,

the

levels

of

circulating

catecholamines increases, and stimulates energy mobilization from adipocytes.
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Figure 1.1 Overview of beta-adrenergic stimulated lipolysis.
Catecholamine binding to (3-adrenergic receptors coupled to Gs heterotrimeric Gproteins activates adenylyl cyclase activity leading to an increase in intracellular
cAMP and subsequent PKA activity. PKA phosphorylates a number of
downstream targets including HSL. ATGL, HSL and MGL catalyze the complete
hydrolysis of triglycerides leading to the release of free fatty acids and glycerol,
(adapted from Langin, 2006)
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1.4.3 Lipogenesis
Lipogenesis is the process of energy storage and encompasses both the
processes of fatty acid synthesis and triacylglycerol synthesis [Kersten, 2001].
Lipogenesis takes place in both adipose tissue and the liver. It is a highly
regulated process that is affected by dietary and hormonal influences such as
insulin and leptin [Coleman et al., 2000], Increases in lipogenesis can lead to an
increase in fat accumulation and the upregulation of a number of lipogenic
enzymes including fatty acid synthase (FAS) and glycerol acyltransferases has
been found in animal models of obesity [Jamdar and Cao, 1995; Guan et al.,
2005].

1.4.3.1 Fatty Acid Synthesis
De novo fatty acid synthesis is used to store excess energy from
carbohydrates in the form of fatty acids [Coleman et al., 2000]. Glucose is the
primary substrate and is broken down and converted into two carbon substrates
that undergo sequential condensation to produce fatty acids. These fatty acids
can then be used in triacylglycerol synthesis. In humans, a high-carbohydrate
diet can increase the expression of lipogenic enzymes and increase their activity
[Kersten, 2001]. This is important because the Western “cafeteria diet” is rich in
both carbohydrates and fat.
1.4.3.1.1 Fatty Acid Synthase
Fatty acid synthase is the central enzyme responsible for the de novo
synthesis of fatty acids [Smith et al., 2003], It functions as a homodimer and is a

multifunctional enzyme that catalyzes all of the reactions necessary to produce
fatty acids. The FAS gene encodes one long polypeptide chain that contains
seven catalytic domains that are connected by linkers. The primary product of
FAS is the 16-carbon fatty acid palmitate which is produced through the
condensation of two carbon units provided by acetyl co-enzyme A (CoA) and
malonyl-CoA, in the presence of NADPH. FAS expression is upregulated in
genetically obese rats [Menendez et al., 2009] and one study found that
lipogenesis and FAS activity were coordinately regulated [Wang et al., 2004], In
human visceral adipose tissue, expression of FAS was positively correlated with
visceral fat area and inversely correlated with insulin sensitivity [Berndt et al.,
2007]. Altogether, these findings suggest a possible role for FAS in the
pathogenesis of obesity and its related metabolic abnormalities.

1.4.3.1.2 Stearoyl-CoA desaturase 1
Stearoyl-CoA desaturase (SCD1) is an endoplasmic reticulum enzyme
that is highly expressed in adipose tissue [Dobrzyn and Ntambi, 2004], It
introduces a single double bond into fatty acyl-CoA substrates which is the rate
limiting step in the synthesis of monounsaturated fatty acids. Monounsaturated
fatty acids comprise the majority of fatty acids found in triglycerides and
phospholipids [Jiang et al., 2005]. Knockout of SCD1 results in mice that are lean
and resistant to diet induced obesity [Dobrzyn and Ntambi, 2004], This resistance
was attributed to an increase in metabolism and a decrease in lipogenesis.
Overall, SCD1 plays an important role in regulating lipid metabolism and SCD1
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inhibition is currently being explored as a treatment for obesity [Dobrzyn and
Ntambi, 2005].

1.4.3.2 Triacylglycerol Synthesis
Triacylglycerol synthesis requires glycerol and fatty acid chains which are
first converted to glycerol-3-phosphate and fatty acyl-CoA respectively [Coleman
and Mashek, 2011]. Glycerol-3-phosphate can be produced from glucose
through glycolysis or produced from glyceroneogenesis [Large et al., 2004], Fatty
acids are primarily derived from dietary sources but are also produced by de
novo fatty acid synthesis. Triacylglycerol synthesis involves the sequential
esterification of fatty acyl-CoA to glycerol-3-phosphate [Takeuchi and Reue,
2009]. These reactions are catalyzed by a number of acyltransferases. Various
knockout mice that are deficient in acyltransferase enzymes have been
generated which results in reduced adipose tissue stores [Coleman and Mashek,
2011 ],

1.4.4 Adipose Tissue and Glucose Uptake
Glucose uptake is an important function of adipose tissue and studies
have shown that glucose is an important regulator of adipocyte metabolism
[Rosen and Spiegelman, 2006]. Adipocytes express both glucose transporter
(GLUT) 1 and GLUT4 glucose transporters [Pedersen et al., 1992]. GLUT1 is
responsible for basal glucose uptake while GLUT4 is involved in insulin
stimulated uptake. In adipocytes, glucose is utilized in the synthesis of the

glycerol-3-phosphate backbone which is required for triglyceride synthesis and
fat deposition. In addition, glucose is also used in de novo fatty acid synthesis.
Glucose transport is the rate limiting factor in glucose utilization and plays an
important role in the development of obesity [Tozzo et al., 1995], In a transgenic
mouse model where GLUT4 was overexpressed in adipocytes, there was a
significant upregulation in the activity of several major metabolic pathways. In
particular, de novo fatty acid synthesis was preferentially increased [Shepherd et
al., 1993]. These mice become obese and the increased adipose tissue mass
was characterized by adipocyte hyperplasia. During the early development of
obesity, adipocytes from fatty Zucker rats have a significant upregulation of both
GLUT1 and GLUT4 expression and concomitant increases in glucose uptake
[Pedersen et al., 1992], Furthermore, there was also a significant increase in the
conversion of glucose to total lipids. Altogether, an increase in glucose uptake
can increase adipocyte metabolic activity and lipogenesis which leads to
increased fat accumulation.

1.4.4.1 Adipose Tissue and Glucose Homeostasis
An increase in glucose uptake can contribute to the development of
obesity. However, once an obese state is reached, insulin resistance can
develop in part through the increased secretion of adipokines such as tumour
necrosis factor alpha [Rosen and Spiegelman, 2006], Muscle, liver and adipose
tissue are the major insulin sensitive tissues in the body and they all play an
important role in whole body glucose homeostasis. Although, adipose tissue

accounts for only 10-15% of insulin-stimulated glucose uptake, there is
accumulating evidence that it plays an important role in the development of
insulin resistance. Insulin resistance is the earliest defect in the development of
type 2 diabetes [Cline et al., 1999], In insulin-resistant states, there is often
impairment in GLUT4 expression in adipose tissue but not muscle [Shepherd and
Kahn,

1999], Furthermore, adipocyte specific knockout of GLUT4 gene

expression was found to induce insulin resistance to a similar degree as a
muscle specific ablation of GLUT4 [Abel et al., 2001]. From these findings, it has
been hypothesized that insulin resistance first develops in adipose tissue which
then spreads to muscle and liver.

1.5 Rationale and Hypothesis
Adipose tissue has recently been identified as a novel source of NPY
biosynthesis [Kos et al., 2007; Kuo et al., 2007; Yang et al., 2008], Its expression
was dramatically upregulated in our early life rat model of visceral obesity [Guan
et al., 2005], in the obese Zucker rat [Yang et al., 2008] and in a diet and stress
induced mouse model of obesity [Kuo et al., 2007], Moreover, NPY was shown to
directly stimulate adipose tissue expansion [Kuo et al., 2007], It is evident that
NPY plays an important peripheral role in the pathogenesis of obesity.
Obesity results from a chronic energy imbalance that can occur through a
decrease in lipolysis and/or an increase in lipogenesis. Furthermore, an increase
in adipocyte glucose uptake can also lead to obesity. Since the mechanisms
underlying NPY’s contribution to obesity remain poorly understood, this study
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investigated the hypothesis that NPY promotes the development of obesity by
inhibiting lipolysis, increasing lipogenesis and increasing glucose uptake. The
overall objective of this study was to determine the role of NPY in regulating
major metabolic pathways in adipocytes.
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Chapter 2
Materials and Methods
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2.1 3T3-L1 Culture and Differentiation
The murine preadipocyte 3T3-L1 cell line was obtained from the American
Type Culture Collection (Manassas, VA). 3T3-L1 cells were cultured and
differentiated, as previously described [Yang et al., 2008], Briefly, they were
cultured in growth medium, consisting of DMEM (Sigma) supplemented with 50
U/ml penicillin, 50 pg/ml streptomycin (Invitrogen) and 10% fetal bovine serum
(Sigma). Cultures were maintained in a humidified incubator at 5% CO2and 37°
C. Medium was replaced every other day. At 2 days after confluence (day 0),
cells were induced to differentiate by the addition of a standard differentiation
cocktail containing 500 pM 3-isobutyl-1-methylxanthine (Sigma), 0.25 pM
dexamethasone (Alpharma, Boucherville, Quebec, Canada), and 1 pg/ml insulin
(Eli Lilly Canada Inc., Toronto, Ontario, Canada). At day 2, the medium was
replaced with growth medium supplemented with 1 pg/ml insulin and then
replaced at days 4 and 6 with growth medium. At day 8, differentiation was 90%
or higher, as determined by Oil red O staining (Fig. 2.1). All treatments were
carried out on differentiated 3T3-L1 adipocytes and preceded by a 2 hour
starving period during which cells were washed and incubated in serum-free
medium. Each treatment was performed in triplicate under serum-free conditions,
and a total of four to six independent experiments were carried out. For each
treatment condition, controls were included and treated for the same time with an
identical volume of the vehicle, as described in detail in figure legends.
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Control

Differentiation Cocktail

Figure 2.1 Oil red O staining of 3T3-L1 cells. 3T3-L1 preadipocytes were
cultured in standard growth medium until confluent. At 2 days after confluence
(day 0), cells were induced to differentiate by the addition of a standard
differentiation cocktail containing 500 pM 3-isobutyl-1-methylxanthine , 0.25 pM
dexamethasone, and 1 pg/ml insulin. At day 2, the medium was replaced with
growth medium supplemented with 1 pg/ml insulin and then replaced at days 4
and 6 with growth medium. At day 8, differentiation is determined by Oil red O
staining. Microphotographs 10 X magnification.
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2.2 Assessment of Lipolysis
Differentiated 3T3-L1 adipocytes were pre-treated without or with 100 nM
of NPY for 30 minutes. After 30 minutes, cells were treated without or with 10 nM
of isoproterenol or with 50 nM of forskolin for 90 minutes. Medium was then
collected and stored at -20°C. Glycerol released into the medium was assessed
using a colorimetric assay (EnzyChrom™ Adipolysis Assay Kit, BioAssay
Systems, Hayward, CA, USA) following the manufacturer’s instructions. The
assay uses an enzymatic reaction to convert glycerol into a colored substrate and
the color intensity of the reaction product is proportional to the glycerol
concentration.

2.3 Measurement of HSL Phosphorylation: Western Blotting
3T3-L1 adipocytes were pre-treated without or with 100 nM of NPY for 30
minutes. After 30 minutes, cells were treated without or with 10 nM of
isoproterenol for 10 minutes. At the end of treatment, cells were lysed in SDS
sample buffer (62.5 mM Tris-HCL, pH 6.8, 2% wt/vol SDS, 10% glycerol, 50mM
dithiothreitol, and 0.01% wt/vol bromphenol blue) and stored at -80°C.
Western blotting was performed as described previously [Yang et al.,
2008]. Briefly, equal volumes of cell lysate were subjected to a standard 10%
SDS-PAGE. After electrophoresis, proteins were then transferred to a PVDF
transfer membrane (Amersham Hybond™-P, GE Healthcare Canada, Baie
D’Urfe, QC, Canada) using a Bio-Rad Mini Transfer Apparatus. The PVDF
membrane was blocked for 1 h at room temperature with 5% milk in TTBS
(0.05% Tween-20 in TBS) and then incubated with primary antibody in TTBS

overnight at 4°C. Phosphorylated HSL protein was detected using the PhosphoHSL (Ser563) Antibody (Cell Signaling; #4139; 1:1000 dilution). After three 10
min washes with TTBS, the membrane was incubated with Anti-Rabbit IgG-HRP
(R&D Systems) secondary antibody (1:1000 dilution) and developed using
chemiluminesence (Western Lightning™ Plus-ECL,

PerkinElmer Life and

Analytical Sciences). The membrane was then exposed to X-ray film (Eastman
Kodak, Rochester, NY, USA). The membrane was stripped by incubation with
stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM Tris-HCI pH
6.7) for 30 min at 55°C. After three 10 min washes in TTBS, the membrane was
blocked as described above and re-probed to detect total HSL protein using the
HSL Antibody (Cell signaling; #4107; 1:1000 dilution).

2.4 Measurement of Lipolytic and Lipogenic Proteins: Western Blotting
3T3-L1 adipocytes were treated with increasing concentrations of NPY for
12, 24 and 48 hours. At the end of treatment, cells were lysed in SDS sample
buffer and stored at -80°C. Cell lysates were subjected to standard western blot
analysis as described above. The primary antibodies were SCD1 antibody (Cell
Signaling, Danvers, MA, USA; #2794), FAS antibody (Cell Signaling; #3819),
perilipin antibody (Cell Signaling; #3470), HSL antibody (Cell Signaling; #4107),
ATGL antibody (Cell Signaling; #2138), GAPDH antibody (Cell Signaling; #2118)
and (3-tubulin antibody (Imgenex Corp., San Diego, CA, USA; IMG-5810A). All
primary antibodies were used at 1:1000 dilutions.
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2.5 [1,2-3H]2-Deoxy-D-Glucose (2-DOG) Uptake
Cells were washed twice with Krebs-Ringer-Hepes (KRH) buffer and
incubated for 15 min without or with NPY (100 nM) and without or with Insulin
(100 nM) in KRH buffer. Subsequently, 0.1 mM 2-DOG containing 0.5 pCi [1,23H] 2-DOG (PerkinElmer Life and Analytical Sciences, Woodbridge, ON, Can)
was added for 10 min. The reaction was terminated by addition of ice-cold
phosphate buffered saline. Cells were washed three times with ice-cold
phosphate buffered saline and then solubilized by the addition of 0.5M NaOH.
The solubilized cell lysate was added to 4 ml of scintillation fluid, and the uptake
of [1,2-3H] 2-DOG was determined by liquid scintillation counting.
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Chapter 3
Results
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3.1 Effects of NPY on Lipolysis
Obesity results from a chronic imbalance between energy storage (i.e.,
lipogenesis) and energy expenditure (i.e., lipolysis) in adipose tissue. Since NPY
expression is upregulated in visceral adipose tissue of our early-life programmed
rat model of increased visceral adiposity [Yang et al., 2008], we hypothesized
that NPY may act directly on adipocytes to inhibit lipolysis and/or stimulate
lipogenesis thereby contributing to the pathogenesis of visceral obesity. As a first
step in examining this hypothesis, we studied the effects of NPY on both basal
and stimulated lipolysis. Since catecholamines are the major lipolytic stimuli in
vivo and they signal through (3-adrenergic receptors [Turtzo et al., 2001; Lafontan
and Langin, 2009], we used isoproterenol, a well-known p-adrenergic agonist, to
stimulate lipolysis. We showed that NPY had no effect on lipolysis under basal
conditions. However, NPY potentiated isoproterenol-stimulated lipolysis by
approximately 30% (Fig. 3.1A; p<0.05).
The P-adrenergic receptors in adipocytes are coupled to the Gs
heterotrimeric g-protein, which activates adenylyl cyclase resulting in an increase
in intracellular levels of cAMP, leading to PKA activation, phosphorylation of
downstream targets, and ultimately increased lipolysis [Duncan et al., 2007], As a
first step in deciphering the molecular mechanisms by which NPY potentiates Padrenergic stimulation of lipolysis, we treated cells with forskolin, a direct
activator of adenylyl cyclase. As shown in Fig. 3.1B, NPY treatment had no effect
on forskolin stimulated lipolysis.
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Figure 3.1 Effects of NPY on basal and stimulated lipolysis. Differentiated
3T3-L1 adipocytes were pretreated with NPY (100 nM) for 30 min, and were then
treated with (A) isoproterenol (ISO; 10nM) or (B) forskolin (FSK; 50 nM) for 90
min. Controls were treated at the same time with an appropriate volume of
vehicle. At the end of treatment, medium was collected, and lipolysis was
determined by measuring glycerol released into the medium using a standard
colorimetric assay. Data are presented as means ± SEM of four independent
experiments, each performed in triplicate, a vs. b, P < 0.05; b vs. c, P < 0.05.
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3.2 Effects of NPY on HSL Phosphorylation
HSL is the rate-limiting enzyme in lipolysis, and its activity is controlled by
the cAMP/PKA signaling pathway. Phosphorylation of HSL by PKA at Ser563,
Ser659, Ser660 is associated with an increase in HSL activity and subsequent
lipolysis [Anthonsen et al., 1998; Holm et al., 2000a]. To determine whether NPY
potentiated isoproterenol-stimulated lipolysis was mediated in part through
enhanced HSL phosphorylation, we studied the effect of NPY on HSL
phosphorylation at Ser563. We found that although it had no effect on HSL
phosphorylation under basal conditions, NPY increased isoproterenol stimulated
HSL phosphorylation (Fig. 3.2).
3.3 Effects of NPY on the Expression of Key Lipolytic Proteins/enzymes
Besides acute regulation, the lipolytic capacity of adipocytes can be
regulated through changes in the expression of critical lipolytic proteins, such as
HSL, ATGL, and perilipin [Langin et al., 2005; Lafontan and Langin, 2009]. The
expression of these proteins/enzymes is decreased in obese states and has
been shown to be regulated by other hormones such as cortisol and insulin
[Kralisch et al., 2005; Jocken et al., 2007]. To ascertain if NPY regulates the
expression of these proteins, we treated 3T3-L1 adipocytes with increasing
concentrations of NPY for 24 h. As shown in Fig. 3.3, NPY treatment did not
change levels of HSL, perilipin, or ATGL protein. Similar results were obtained
when adipocytes were treated with NPY for 12 and 48 h (data not shown). Cells
appeared normal when checked after treatment periods just prior to protein
collection.

33

NPY ISO -

+
-

+

+
+

Figure 3.2 Effects of NPY on hormone sensitive lipase (HSL)
phosphorylation. Differentiated 3T3-L1 adipocytes were pretreated with NPY
(100 nM) for 30 min, and were then treated with isoproterenol (ISO; 10 nM) for 10
min. Controls were treated at the same time with an appropriate volume of
vehicle. At the end of treatment, cell lysates were prepared, and HSL
phosphorylation at serine 563 was determined by western blotting using
antibodies specific for phosphorylated HSL and total HSL proteins. Results of a
representative western blotting are shown. Data are presented as means ± SEM
of four independent experiments, each performed in triplicate, a vs. b, P < 0.05; b
vs. c, P < 0.05.
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Figure 3.3 Effects of NPY on the expression of selected key lipolytic
proteins/enzymes. Differentiated 3T3-L1 adipocytes were treated with
increasing concentrations of NPY for 24 h. At the end of treatment, cell lysates
were prepared, and subjected to western blot analysis. Levels of three key
proteins controlling lipolysis were determined using antibodies specific for
hormone sensitive lipase (HSL), perilipin and adipose triglyceride lipase (ATGL).
GAPDH was used as a loading control. Data are presented as means ± SEM of
four independent experiments.
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3.4 Effects of NPY on the Expression of Key Lipogenic Enzymes
Energy balance in adipocytes is controlled by lipolysis and lipogenesis.
FAS and SCD1 are important lipogenic enzymes that were found to be
upregulated in the visceral adipose tissue of obese MPR offspring [Guan et al.,
2005]. In other studies, the expression of these enzymes was found to be
upregulated in obese animals and correlated with fat accumulation in humans
[Boizard

et

al.,

1998;

Berndt

et

al.,

2007],

Furthermore,

chronic

intracerebroventricular NPY administration led to increased adipose tissue
lipogenesis in normal rats [Zarjevski et al., 1993], These findings led us to study
the effect of NPY on the expression of FAS and SCD1. We treated 3T3-L1
adipocytes with increasing concentrations of NPY for 24 h. As shown in Fig. 3.4,
NPY treatment did not change levels of SCD1 and FAS protein. Similar results
were obtained when adipocytes were treated with NPY for 12 and 48 h (data not
shown). Cells appeared normal when checked after treatment periods just prior
to protein collection.
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Figure 3.4 Effects of NPY on the expression of selected key lipogenic
enzymes. Differentiated 3T3-L1 adipocytes were treated with increasing
concentrations of NPY for 24 h. At the end of treatment, cell lysates were
prepared, and subjected to western blot analysis. Levels of two critical lipogenic
enzymes were determined using antibodies specific for fatty acid synthase (FAS)
and stearoyl-CoA desaturase 1 (SCD1). (3-tubulin was used as a loading control.
Data are presented as means ± SEM of four independent experiments.
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3.5 Effects of NPY on Glucose Uptake
Besides energy mobilization and energy storage, glucose uptake is
another critical metabolic process in adipocytes [Rosen and Spiegelman, 2006],
Glucose transport is a key regulatory step in glucose utilization in adipocytes.
One study found that ICV administration of NPY increased glucose uptake by
adipose tissue which could contribute to increased fat accumulation [Zarjevski et
al., 1994], To determine if NPY affects adipocyte glucose uptake, we treated 3T3L1 adipocytes with NPY in the absence and presence of insulin, the primary
stimulator of glucose uptake. As expected, insulin increased glucose uptake by
approximately 400%. However, NPY treatment had no effect on basal or insulin
stimulated glucose uptake (Fig. 3.5).
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Figure 3.5 Effects of NPY on glucose uptake. Differentiated 3T3-L1 adipocytes
were treated with NPY (100 nM), insulin (100 nM) or in combination (100 nM
each) for 15 minutes, following which 0.1 mM of unlabeled 2-deoxy-D-glucose
3
containing 0.5 pCi [1,2- H] 2-deoxy-D-glucose was added to the medium. After a
10 min incubation, cells were washed, solubilized and uptake of [1,2- H] 2-deoxyD-glucose was measured using a liquid scintillation counter. Data are presented
as means ± SEM of three independent experiments, each performed in triplicate,
a vs. b, P < 0.001.
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4.1 General Discussion
Adipose tissue is a novel site of NPY biosynthesis, and NPY acts locally to
promote adipogenesis thereby contributing to the pathogenesis of obesity [Kuo et
al., 2007; Yang et al., 2008], Despite these important observations, the role of
NPY in regulating adipocyte metabolism is poorly understood. The present
findings reveal a novel role for NPY in potentiating (3-adrenergic stimulation of
lipolysis. Furthermore, our data suggest that this potentiation likely occurs
upstream of adenylyl cyclase activation, and is mediated at least in part through
enhanced phosphorylation of HSL, a rate limiting enzyme in lipolysis.
Lipolysis is a critical metabolic function of adipocytes, which liberates
glycerol and free fatty acids for use by other tissues. In this study, we examined
the role of NPY in regulating basal and (3-adrenergic stimulated lipolysis.
Although it did not affect lipolysis under basal conditions, NPY potentiated
isoproterenol-stimulated lipolysis. This is an unexpected finding, and appears to
contradict several previous reports in which NPY was found to inhibit both basal
and stimulated lipolysis in isolated adipocytes from dogs, rats, and humans as
well as 3T3-L1 adipocytes [Valet et al., 1990; Castan et al., 1994; Labelle et al.,
1997; Turtzo et al., 2001; Kos et al., 2007], These discrepancies may be
explained by differences in experimental conditions between our present study
and those published previously. In previous studies, lipolysis was stimulated by
adenosine deaminase, which removes the inhibitory effect of adenosine (a potent
inhibitor of lipolysis), and/or isoproterenol. Importantly, the magnitude of lipolytic
stimulation in these studies was much greater than that in the present study (~4-

fold vs. ~2-fold) owing to the use of a different stimulus or higher concentrations
of isoproterenol (100 nM vs. 10 nM). Thus, the effect of NPY on stimulated
lipolysis likely depends on the strength of lipolytic stimulation. In support of this
contention, we found that NPY lost its ability to potentiate isoproterenolstimulated lipolysis at higher concentrations of isoproterenol (>20 nM).
Our present findings that NPY promotes lipolysis by potentiating |3adrenergic receptor signaling are intriguing, and beg the question of the
underlying molecular mechanisms. As a first step in deciphering the molecular
mechanisms, we examined the effects of NPY on forskolin (a direct activator of
adenylyl cyclase) stimulated lipolysis. We found that NPY did not potentiate
forskolin stimulated lipolysis, which suggests that NPY acts upstream of adenylyl
cyclase to potentiate (3-adrenergic stimulated lipolysis. This effect was not due to
maximal stimulation of lipolysis by forskolin because lipolysis can be increased
by at least several fold in adipocytes [Lafontan and Langin, 2009]. Our present
findings are similar to those reported previously showing that NPY potentiated aadrenergic receptor-mediated vasoconstriction [Edvinsson et al., 1984; Domoso
et al., 1993; Fallgren et al., 1993]. Furthermore, NPY had no effect on
vasoconstriction when applied alone, which is similar to our observations that
NPY did not affect basal lipolysis. Our lab [Yang et al., 2008] and others [Gericke
et al., 2009] have reported that the

receptor subtype is expressed in 3T3-L1

cells and the Yi receptor has been implicated in potentiating a-adrenergic
mediated vasoconstriction. The crosstalk between NPY and (3-adrenergic
signaling pathways is significant given the fact that norepinephrine and NPY are

co-stored in sympathetic neurons (Cannon et al., 1986). Thus, we propose that
the interaction between these two signaling pathways may provide an additional
layer in the precise control of lipolysis (Fig. 4.1).
HSL activity is tightly controlled by the phosphorylation pattern of HSL
[Holm et al., 2000a].To determine if NPY potentiation of isoproterenol-stimulated
lipolysis is mediated by increased HSL phosphorylation, we examined the effects
of NPY on HSL phosphorylation under basal and stimulated conditions. Similar to
its effect on lipolysis, NPY did not affect HSL phosphorylation under nonstimulated conditions but enhanced isoproterenol-induced HSL phosphorylation,
suggesting that the effect of NPY on (3-adrenergic-stimulated lipolysis is mediated
at least in part by increased HSL phosphorylation (Fig. 4.1).
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Figure 4.1 Schematic of the molecular mechanisms underlying
neuropeptide Y (NPY) potentiation of beta-adrenergic stimulated lipolysis.
NPY binds to the Yi receptor in 3T3-L1 adipocytes and potentiates (+) betaadrenergic signaling induced by isoproterenol (ISO). This potentiation occurs
through an unknown (?) mechanism that is upstream of adenylyl cyclase (AC)
activation. Activation of the beta-adrenergic receptor stimulates AC activity
leading to an increase in intracellular cAMP and subsequent PKA activity. PKA
phosphorylâtes serine residues of hormone sensitive lipase (HSL) which
increases its activity leading to an increase in lipolysis.

Besides

acute

regulation

of

lipolysis

through

the

reversible

phosphorylation of proteins, lipolysis is also regulated at the level of lipolytic gene
expression [Lafontan and Langin, 2009]. When the genes encoding critical
lipolytic proteins are knocked out in mice, lipolysis and adipocyte phenotype are
significantly affected. Mice deficient in HSL have a 70% reduction in lipolysis in
adipose tissue and adipocytes are enlarged two-fold when compared to wild type
animals [Osuga et al., 2000; Schweiger et al., 2006]. When ATGL is knocked out,
isoproterenol-stimulated lipolysis is reduced by 75% and adipocytes are enlarged
by 40% [Haemmerle et al., 2006]. In contrast, basal lipolysis in perilipin knockout
mice is increased by 3-fold and adipocytes are 62% smaller [Martinez-Botas et
al., 2000]. Although NPY is known to regulate lipolysis, its role in regulating the
expression of these important lipolytic proteins had not been previously explored.
Therefore, in the present study we examined the effect of NPY on the expression
of HSL, ATGL and perilipin. We found that NPY had no effect under a variety of
treatment conditions. Taken together, our present findings suggest that NPY
regulates lipolysis through mechanisms not involving changes in the expression
of lipolytic enzyme/proteins.
The synthesis of lipids and triglycerides involves numerous steps and
enzymes [Wolfgang and Lane, 2006]. Our previous DNA microarray data showed
that the expression of two critical lipogenic enzymes, FAS and SCD1 , was
upregulated in visceral adipose tissue of an early-life programmed rat model of
increased visceral adiposity [Guan et al., 2005]. Furthermore, ICV administration
of NPY to rats increased lipogenesis in adipose tissue [Zarjevski et al., 1993].

However, it remained unknown if NPY regulates the expression of lipogenic
enzymes. Therefore, in the present study we investigated the effect of NPY on
the expression of SCD1 and FAS. Under the conditions of the present study,
NPY did not affect either SCD1 or FAS expression, suggesting that NPY may
regulate lipogenesis through mechanisms that do not involve altered expression
of SCD1 and FAS. Alternatively, NPY may affect the expression of other
important lipogenic enzymes such as the acyltransferases that catalyze
triacylglycerol synthesis.
Adipose tissue is a major insulin sensitive tissue and glucose uptake is
another major function of adipocytes [Smith, 2002]. Glucose uptake and
utilization is increased in the development of obesity and increased uptake in
adipose tissue of our early life model of visceral adiposity could be one
mechanism contributing to adipocyte hyperplasia [Shepherd et al., 1993; Guan et
al., 2005]. Furthermore, ICV administration of NPY to normal rats increased
glucose utilization by adipose tissue but it was not known if NPY has a direct
effect on glucose uptake at the adipocyte level [Zarjevski et al., 1994]. We
investigated whether NPY affected basal or insulin stimulated glucose uptake but
did not find a role for NPY in regulating these processes. This suggests that the
effects of NPY on adipose tissue glucose metabolism are mediated centrally and
other mechanisms such as increases in preadipocyte proliferation underlie the
hyperplastic obesity seen in the early-life rat model of visceral adiposity.
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4.2 Summary and Conclusions
In summary, we report here a novel cross talk between NPY and (3adrenergic receptor signaling pathways by demonstrating that NPY potentiates
isoproterenol stimulated lipolysis and HSL phosphorylation. This potentiation
likely occurs upstream of adenylyl cyclase activation since NPY did not potentiate
FSK stimulated lipolysis. We did not find an effect of NPY treatment on lipolytic
enzyme/protein expression. Furthermore, we did not find a role for NPY in
regulating lipogenic enzyme expression and glucose uptake in adipocytes.
Altogether, these present findings add a new dimension to our understanding of
the dynamic role NPY plays in regulating energy balance. Overall, this study lays
the groundwork for future explorations of the effects of NPY in regulating
adipocyte metabolism.

4.3 Future Directions
The novel cross talk between the NPY and (3-adrenergic signaling
pathways opens up a number of interesting avenues and questions for future
investigation. Importantly, the results of this study using the 3T3-L1 cell line will
need to be confirmed in vivo. The physiological relevance and role of the
interaction between these pathways in normal and pathological conditions will
need to be assessed. Another logical extension of this study is further
investigation into the mechanisms involved in this potentiation effect. Both the
signaling events following NPY receptor activation and the molecular changes
facilitating the enhancement of (3-adrenergic signaling need to be explored.

Furthermore, isoproterenol activates both (31 and (32 adrenergic receptors and it
is unclear whether NPY is able to potentiate the signaling of both receptor
subtypes.
NPY is co-stored and co-released along with norepinephrine in central
neurons and peripheral sympathetic neurons. As such, the NPY potentiation of (3adrenergic signaling could be physiologically relevant in other systems or tissues
such as the gut and adrenal glands that are innervated by such neurons.
Additionally, in different areas of the brain, NPY is co-stored with other
neurotransmitters such as GABA and acetylcholine [Wan and Benjamin, 1995],
To date, NPY signaling has been shown to potentiate the signaling of aadrenoreceptors and (3-adrenoreceptors. The possible interaction of NPY
receptor signaling with other neurotransmitter signaling pathways is another
interesting future area of questioning.
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